Aurobindo arm terminates paediatric pentavalent vax licence pact with Hilleman Labs
Aurobindo Pharma has terminated its licensing agreement with Hilleman Laboratories Singapore for a paediatric pentavalent vaccine candidate, effective March 5, 2025. The company clarifies that the early-stage vaccine asset's termination will not have any substantial impact on its financials or subsidiaries.
Aurobindo Pharma has terminated its licensing agreement with Hilleman Laboratories Singapore for a paediatric pentavalent vaccine candidate, effective March 5, 2025. The company clarifies that the early-stage vaccine asset's termination will not have any substantial impact on its financials or subsidiaries.
